# Development and External Validation of a 1 Mixed-Effects Deep Learning Model to 2 **Diagnose COVID-19 from CT Imaging** 3

- 4 Joshua Bridge, Yanda Meng, Wenyue Zhu, Thomas Fitzmaurice, Caroline McCann, Cliff Addison,
- 5 Manhui Wang, Cristin Merritt, Stu Franks, Maria Mackey, Steve Messenger, Renrong Sun, Yitian
- 6 Zhao, Yalin Zheng
- 7 Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, L7
- 8 8TX Joshua Bridge PhD. Student, Yanda Meng PhD. Student, Wenyue Zhu PhD. Student, Thomas
- 9 Fitzmaurice Clinical Research Fellow in Respiratory Medicine, Yalin Zheng Reader in Ophthalmic
- 10 Imaging. Department of Respiratory Medicine, Liverpool Heart and Chest Hospital NHS Foundation
- Trust, Liverpool, United Kingdom, L14 3PE Thomas Fitzmaurice Clinical Research Fellow in 11
- 12 Respiratory Medicine. Department of Radiology, Liverpool Heart and Chest Hospital NHS Foundation
- 13 Trust, United Kingdom, L14 3PE Caroline McCann Consultant Cardiothoracic Radiologist. Advanced
- 14 Research Computing, University of Liverpool, Liverpool, United Kingdom, L69 3BX Cliff Addison,
- 15 Manhui Wang. Alces Flight Limited, Bicester, United Kingdom, OX26 4PP Cristin Merritt, Stu Franks.
- 16 Amazon Web Services, 60 Holborn Viaduct, London EC1A 2FD Maria Mackey, Steve Messenger.
- 17 Department of Radiology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine,
- 18 Hubei University of Chinese Medicine, Wuhan 430000, China Renrong Sun. Cixi Institute of
- 19 Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering, Chinese
- 20 Academy of Sciences, Ningbo 315201, China Yitian Zhao.
- 21
- 22 Correspondence to:
- 23 Dr Yalin Zheng,
- 24 Institute of Life Course and Medical Sciences,
- 25 University of Liverpool,
- 26 William Henry Duncan Building,
- 27 6 West Derby Street,
- 28 Liverpool,
- 29 L7 8TX,
- 30 Yalin.Zheng@liverpool.ac.uk
- 31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 1 Abstract

- 2 Objectives
- 3 To develop and externally geographically validate a mixed-effects deep learning model to diagnose
- 4 COVID-19 from computed tomography (CT) imaging following best practice guidelines and assess the
- 5 strengths and weaknesses of deep learning COVID-19 diagnosis.
- 6 Design
- 7 Model development and external validation with retrospectively collected data from two countries.
- 8 Setting
- 9 Hospitals in Moscow, Russia, collected between March 1, 2020, and April 25, 2020. The China
- 10 Consortium of Chest CT Image Investigation (CC-CCII) collected between January 25, 2020, and
- 11 March 27, 2020.
- 12 Participants
- 13 1,110 and 796 patients with either COVID-19 or healthy CT volumes from Moscow, Russia, and
- 14 China, respectively.
- 15 Main outcome measures
- 16 We developed a deep learning model with a novel mixed-effects layer to model the relationship
- 17 between slices in CT imaging. The model was trained on a dataset from hospitals in Moscow, Russia,
- 18 and externally geographically validated on a dataset from a consortium of Chinese hospitals. Model
- 19 performance was evaluated in discriminative performance using the area under the receiver
- 20 operating characteristic (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative
- 21 predictive value (NPV). In addition, calibration performance was assessed using calibration curves,
- 22 and clinical benefit was assessed using decision curve analysis. Finally, the model's decisions were
- 23 assessed visually using saliency maps.
- 24 Results
- 25 External validation on the large Chinese dataset showed excellent performance with an AUROC of
- 26 0.936 (95%CI: 0.910, 0.961). Using a probability threshold of 0.5, the sensitivity, specificity, NPV, and
- 27 PPV were 0.753 (0.647, 0.840), 0.909 (0.869, 0.940), 0.711 (0.606, 0.802), and 0.925 (0.888, 0.953),
- 28 respectively.
- 29 Conclusions
- 30 Deep learning can reduce stress on healthcare systems by automatically screening CT imaging for
- 31 COVID-19. However, deep learning models must be robustly assessed using various performance
- 32 measures and externally validated in each setting. In addition, best practice guidelines for
- 33 developing and reporting predictive models are vital for the safe adoption of such models.

### **Statements** 1

- 2 The authors do not own any of the patient data, and ethics approval was not needed. The lead
- author affirms that this manuscript is an honest, accurate, and transparent account of the study 3
- 4 being reported, that no important aspects of the study have been omitted, and that any
- 5 discrepancies from the study as planned (and, if relevant, registered) have been explained. Patients
- 6 and the public were not involved in the study.

### Funding 7

- 8 This study was funded by EPSRC studentship (No. 2110275), EPSRC Impact Acceleration Account
- 9 (IAA) funding, and Amazon Web Services.

### Summary 10

- What is already known on this topic 11
- 12 Deep learning can diagnose diseases from imaging data automatically •
- Many studies using deep learning are of poor quality and fail to follow current best practice 13 • guidelines for the development and reporting of predictive models 14
- Current methods do not adequately model the relationship between slices in CT volumetric 15 • 16 data
- What this study adds 17
- 18 • A novel method to analyse volumetric imaging data composed of slices such as CT images 19 using deep learning
- 20 Model developed following current best-practice guidelines for the development and 21 reporting of prediction models
- 22

perpetuity. It is made available under a CC-BY 4.0 International license .

### Introduction 1

- 2 Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by severe acute
- 3 respiratory syndrome coronavirus 2 (SARS-CoV-2). Virus clinical presentation ranges from mild cold-
- 4 like symptoms to severe viral pneumonia, which can be fatal.<sup>1</sup> While some countries have achieved
- 5 relative control through lockdowns, future outbreaks and new strains are expected to continue, with
- 6 many experts believing the virus is here to stay.<sup>2</sup> Detection and isolation is the most effective way to
- 7 prevent further spread of the virus. Even with effective vaccines becoming widely available, with the
- 8 threat of continued waves and new potentially vaccine-resistant variants, it is vital to further
- 9 develop diagnostic tools for COVID-19. These tools will likely also apply to future outbreaks of other
- 10 similar diseases as well as common diseases such as pneumonia.
- 11 The diagnosis of COVID-19 is usually determined by Reverse Transcription Polymerase Chain
- 12 Reaction (RT-PCR), but this is far from being a gold standard. A negative test does not necessarily
- 13 indicate a negative diagnosis, with one recent review finding that RT-PCR has a real-world sensitivity
- 14 of around 70% and a specificity of 95%.<sup>3</sup> Furthermore, an individual patient data systematic review<sup>4</sup>
- 15 found that RT-PCR often fails to detect COVID-19, and early sampling is key to reducing false
- 16 negatives. Therefore, these tests are often more helpful to rule in COVID-19 rather than ruling out.
- 17 If a patient presents with symptoms of COVID-19, but an RT-PCR test is negative, then further tests
- 18 are often required.<sup>1</sup> Consecutive negative tests with at least a one-day gap are recommended;
- 19 however, this still does not guarantee that the patient is negative for COVID-19.<sup>5</sup> Computed
- 20 tomography (CT) can play a significant role in diagnosing COVID-19.<sup>6</sup> Given the excessive number of
- 21 COVID-19 cases worldwide and the strain on resources expected, automated diagnosis might reduce
- 22 the burden on reporting radiologists.
- 23 CT images are made up of many slices, creating a three dimensional (3D)-like structure. Previous
- 24 approaches, such as those used by Li et al.<sup>7</sup> and Bai et al.,<sup>8</sup> treat the image as separate slices and use
- 25 a pooling layer to concatenate the slices. An alternative approach assumes the slices form a 3D
- 26 structure and use a 3D CNN, such as that proposed in CoviNet.<sup>9</sup> A fundamental limitation of these
- 27 methods is the need for the same number of slices as their inputs, but the number of slices often
- 28 varies between different CT volumes. Instead, we propose using a novel mixed-effects layer to
- 29 consider the relationship between slices in each scan. Mixed-effects models are commonly used in
- 30 traditional statistics,<sup>1011</sup> but we believe this is the first time that mixed-effects models have been
- utilised in such a way. It has been observed that some lobes of the lung are more often affected by 31
- 32 COVID-19 than others<sup>12 13</sup> with lower lobe distribution being a prominent feature of COVID-19,<sup>14</sup> the
- 33 fixed-effects take this into account by considering where each slice is located within the scan.

34 Deep learning has shown great potential in the automatic classification of disease, often achieving expert-level performance. Such models could screen and monitor COVID-19 by automatically 35 analysing routinely collected CT images. As observed by Wynants et al.<sup>15</sup> and Roberts et al.,<sup>16</sup> many 36 37 models are already developed to diagnose COVID-19, which often obtain excellent discriminative 38 performance; however, very few of these models, if any, are suitable for clinical use, mainly due to a 39 lack of robust analysis and reporting. These models often suffer from common pitfalls, making them 40 unsuitable for broader adoption. Roberts et al.<sup>16</sup> identified three common areas in which models 41 often fail these are: (1) a lack of adequately documented methods for reproducibility, (2) failure to 42 follow established guidelines and best practices for the development of deep learning models, and 43 (3) an absence of external validation displaying the model's applicability to a broader range of data 44 outside of the study sample. Failure to address these pitfalls leads to profoundly flawed and biased 45 models, making them unsuitable for deployment.

- 1 In this work, we aim to address the problems associated with previous models by following
- guidelines for the reporting<sup>17 18</sup> and development<sup>19</sup> of prediction models to ensure that we have 2
- rigorous documentation allowing the methods developed here to be replicated. In addition, we will 3
- 4 make code and the trained model publicly available at [github.com/JTBridge/ME-COVID19] to
- 5 promote reproducible research and facilitate adoption. Finally, we use a second dataset from a
- 6 country other than the development dataset to externally validate the model and report a range of
- 7 performance measures evaluating the model's discrimination, calibration, and clinical usefulness.
- 8 Hence, our main aim is to develop a mixed-effects deep learning model to accurately classify images
- 9 as healthy or COVID-19, following best practice guidelines. Our secondary aim is to show how deep
- 10 learning predictive algorithms can satisfy current best practice guidelines to create reproducible and
- 11 less biased models.

### Methods 12

- Our proposed method consists of a feature extractor and a two-stage generalised linear mixed-13
- effects model (GLMM),<sup>20</sup> with all parameters estimated within the deep learning framework using 14
- 15 backpropagation. First, a series of CT slices forming a CT volume is input to the model. In our work,
- 16 we use 20 slices. Next, a convolutional neural network (CNN) extract relevant features from the
- 17 model and creates a feature vector for each CT slice. Then, a mixed-effects layer concatenates the
- 18 feature vectors into a single vector. Finally, a fully connected layer followed by a sigmoid activation
- 19 gives a probability of COVID-19 for the whole volume. The mixed effects and fully connected layer
- 20 with sigmoid activation are analogous to a linear GLMM in traditional statistics. The overall
- 21 framework is shown in Figure 1.



- Figure 1: Diagram of the overall framework. Twenty slices are chosen from a CT volume. Each slice is 23
- 24 fed into a CNN with shared weights, which outputs a feature vector of length 2048 for each image.
- The feature vectors form a 20-by-2048 fixed effects matrix, X, for the GMM model with a random-25
- 26 effects matrix, Z, consisting of an identity matrix. A mixed-effects model is used to model the
- 27 relationship between slices. Finally, a fully connected layer and sigmoid activation return a
- 28 probability of the diagnosis.

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 1 Feature extractor

- For the feature extractor, we use a CNN. In this work, we chose InceptionV3<sup>21</sup> as it is relatively 2
- efficient and commonly used. InceptionV3 outputs a feature vector of length 2048. To reduce the 3
- 4 time needed to reach convergence, we pretrained the CNN on ImageNet.<sup>22</sup> A CNN is used for each
- 5 slice, with shared weights between CNNs; this reduces the amount of computational power
- 6 required. Following the CNN, we used a global average pooling layer to reduce each image to a
- 7 feature vector for each slice. We then added a dropout of 0.6 to improve generalizability to unseen
- 8 images. We form the feature vectors into a matrix of shape  $20 \times 2048$ . Although we used
- 9 InceptionV3<sup>21</sup> here, other networks would also work and may provide better performance on other
- 10 similar tasks. We then need to concatenate these feature vectors into a single feature vector for the
- 11 whole volume; normally, pooling is used, in our work we propose using a mixed-effects models.
- 12 Mixed-effects network

- 13 We propose utilising a novel mixed-effects layer to model the relationship between slices. Mixed-
- 14 effects models are a statistical model consisting of a fixed-effects part and a random-effects part.
- The fixed-effects part models the relationship within the CT slice; the random effects can model the 15
- spatial correlation between CT slices within the same image.<sup>11</sup> For volumetric data, the number of 16
- slices may differ significantly due to various factors such as imaging protocol and the size of the 17
- patient. Some volumes may have fewer images than the model is designed to use, which leads to 18
- 19 missing data. Mixed-effects models can deal with missing data provided the data are missing at
- 20 random. The mixed-effects model is given by

21 
$$Y_i = X_i \alpha + Z_i \beta + e_i$$

- where  $Y_i$ ,  $X_i$ ,  $Z_i$ ,  $e_i$  are vectors of outcomes, fixed effects design matrix of shape  $20 \times 2048$ , 22
- random effects design matrix of shape  $20 \times 20$ , and vector of error unknown random errors of the 23
- ith patient of shape 20, respectively, and  $\alpha$ ,  $\beta$  are fixed and random effects parameters, both of 24
- length 20. We assume that the random effects  $\beta$  are normally distributed with 0 and variance G 25
- $\beta \sim N(0,G)$ 26
- 27 We also assume independence between the random effects and the error term.
- 28 The fixed effects design matrix, X, is made up of the feature vectors output from the feature
- 29 extraction network. For the random effects design matrix, Z, we use an identity matrix with the
- 30 same size as the number of slices; in our experiments, this is 20. The design matrix is then given by

$$\mathbf{Z}_{20\times 20} = \begin{bmatrix} 1 & 0 & \dots & 0 & 0 \\ 0 & 1 & \dots & 0 & 0 \\ \vdots & \ddots & \vdots \\ 0 & 0 & \dots & 1 & 0 \\ 0 & 0 & \dots & 0 & 1 \end{bmatrix}$$

- This matrix easily generalises to any number of slices. If the distance between slices is not uniform, 32
- 33 the values can be altered accordingly. We assumed no particular correlation matrix. We included the
- fixed and random intercept in the model. All parameters for the mixed-effects layer were initialised 34
- 35 using the Gaussian distribution with mean 0 and standard deviation 0.05.
- 36 A type of mixed-effects modelling has previously been combined with deep learning for gaze
- 37 estimation.<sup>23</sup> However, their mixed-effects method is very different from our proposed method;
- 38 they used the same design matrix for fixed and random effects. In addition, they also estimated
- 39 random-effects parameters with an expectation-maximisation algorithm, which was separate from
- 40 the fixed effects estimation, which used deep learning. In our work, we utilise a spatial design matrix

- 1 to model the spatial relationship between slices and estimate parameters within the deep learning
- 2 framework using backpropagation without the need for multiple stages.
- 3 Loss function
- 4 As the parameters in the model are all estimated using backpropagation, we must ensure that the
- 5 assumption of normally distributed random effects parameters with mean zero is valid. We achieve
- 6 this by introducing a loss function for the random effects parameters, which enforces a mean,
- 7 skewness, and excess kurtosis of 0. We measure skewness using the adjusted Fisher–Pearson
- 8 standardised moment coefficient

9 
$$Skew(\beta) = \frac{\sqrt{n(n-1)}}{n-2} \frac{E\left[\left(\beta - \bar{\beta}\right)^3\right]}{\left(E\left[\left(\beta - \bar{\beta}\right)^2\right]\right)^{3/2}}$$

10 and the excess kurtosis using

11 
$$Kurt(\beta) - 3 = \frac{1}{n^2} \sum_{i=1}^{n} \left( \frac{E\left[ (\beta - \bar{\beta})^4 \right]}{\left( E\left[ (\beta - \bar{\beta})^2 \right] \right)^2} - 3 \right),$$

12 where *n* is the length of 
$$\beta$$
,  $\overline{\beta}$  is the mean of  $\beta$  and  $E[\cdot]$  is the expectation function. The Gaussian

13 distribution has a kurtosis of 3; therefore, the excess kurtosis is given by the kurtosis minus 3. This

14 formula for this fixed-effects parameters loss function which we aim to minimise, is then given by

15 
$$L_{fixed} = |E(\beta) + Skew(\beta) + Kurt(\beta) - 3|.$$

16 For the classification, we use the Brier Score<sup>24</sup> as the loss function, which is given by

17 
$$L_{Brier} = \frac{1}{N} \sum_{i=1}^{N} (p_i - o_i)^2$$

18 where N is the total number of samples,  $p_i$  is the predicted probability of sample *i* and  $o_i$  is the

19 observed outcome of sample *i*. The Brier score is the same as the mean squared error of the

20 predicted probability.

21 We chose to use the Brier Score over the more commonly used binary cross-entropy because it can

22 be decomposed into two components: refinement and calibration. Calibration is often overlooked in

23 deep learning models but is vital to assess the safety of any prediction model. The refinement

24 component combines the model's resolution and uncertainty and measures the model's

discrimination. The calibration component can be used as a measure of the model calibration.

26 Therefore, the Brier Score can be used to optimize both the discrimination and calibration of the

27 model. The overall loss function is given by

$$L = L_{Brier} + L_{fixed}.$$

A scaling factor could be introduced to weight one part of the loss function as more important than the other; however, we give both parts of the loss function equal weighting in our work.

- 31 We also transformed the labels as suggested by Platt<sup>25</sup> to reduce overfitting. The negative and
- 32 positive labels become

33 
$$o_{-} = \frac{1}{N_{-} + 2}$$

perpetuity. It is made available under a CC-BY 4.0 International license .

- 1 and
- 2

$$o_{+} = \frac{N_{+} + 1}{N_{+} + 2}$$

respectively, where  $N_{-}$  and  $N_{+}$  are the total number of negative and positive cases in the training set. This is similar to label smoothing as commonly used in deep learning, but the new targets are

5 chosen by applying Baye's Rule to the out-of-sample data to prevent overfitting.

6 Classification layer

7 The output of the mixed-effects layer is a single vector, which is the same length as the number of

8 slices used. For example, in our work, we had a vector of length 20. Furthermore, we used a fully

9 connected layer with sigmoid activation to obtain a probability of the scan showing COVID-19; the

10 sigmoid activation is analogous to the logistic link function in traditional statistics. Finally, we added

an L1 regularisation term of 0.1 and an L2 regularisation term of 0.01 to the kernel to reduce

12 overfitting.

## 13 Model performance

14 Many deep learning models focus on assessing discriminative performance only, using measures

15 such as the area under the receiver operating characteristic curve (AUROC), sensitivity, and

16 specificity. To better understand the model performance and impact, we report performance

17 measures in three broad areas: discrimination, calibration, and clinical usefulness.<sup>26</sup> Discrimination

assesses how well a model can discriminate between healthy and COVID-19 positive patients.

19 Models with excellent discriminative performance can still produce unreliable results, with vastly

20 overestimated probabilities regardless of the true diagnosis.<sup>27</sup> Model calibration is often overlooked

and rarely reported in deep learning, if at all; however, poorly calibrated models can be misleading

and lead to dangerous clinical decisions.<sup>27</sup> Calibration can be assessed using four levels, with each
level indicating better calibration than the last.<sup>28</sup> The fourth and most stringent level (strong

calibration) requires the correct model to be known, which in turn requires predictors to be non-

25 continuous, and an infinite amount of data to be used and is therefore considered utopic. We

26 consider the third level (moderate calibration) using calibration curves. Moderate calibration will

ensure that the model is at least not clinically harmful. Finally, measures of clinical usefulness assess

28 the clinical consequences of the decision and acknowledge that a false positive may be more or less

29 severe than a false negative.

30 Firstly, the discriminative performance is assessed using AUROC using the pROC package in R<sup>29</sup>, with

31 confidence intervals constructed using DeLong's<sup>30</sup> method. For sensitivity, specificity, positive

32 predictive value (PPV), and negative predictive value (NPV), we use the epiR<sup>31</sup>package in R;<sup>29</sup> with

33 95% confidence intervals constructed using Jeffrey's prior.<sup>32</sup> We report performance at a range of

34 probability thresholds to demonstrate how the thresholds can be adjusted to reduce false positives

35 or false negatives depending on the setting.<sup>33</sup> Secondly, we assess model calibration using

36 calibration curves created using the CalibrationCurves package,<sup>28</sup> which is based on the rms<sup>34</sup>

37 package. Finally, we assess the clinical usefulness of the model using decision curve analysis.<sup>35</sup> Net

38 benefits are given at various thresholds, and models which reach zero net benefit at higher

39 thresholds are considered more clinically useful. Two brief sensitivity analyses are performed, one

40 assessing the model's ability to deal with missing data and the other assessing its ability to deal with

41 noise. To improve the model's interpretability and reduce the black-box nature, we produce saliency

42 maps<sup>36</sup> that show which areas of the image are helpful to the model in the prediction. We also check

43 the assumption of normally distributed random-effects parameters.

perpetuity. It is made available under a CC-BY 4.0 International license .

#### Comparison models 1

- 2 To assess the added benefit of using our mixed-effects method, we compare against networks that
- 3 use alternative methods. Both COVNet<sup>7</sup> and a method proposed by Bai et al.<sup>8</sup> propose deep learning
- 4 models that consider the slices separately before concatenating the features using max pooling.
- 5 COVNet uses a ResNet50<sup>37</sup> CNN to extract features and pooling layers to concatenate the features
- 6 before a fully connected classification layer. The model proposed by Bai et al. uses EfficientNetB4<sup>38</sup>
- 7 to extract features followed by a series of full-connected layers with batch normalisation and
- 8 dropout; average pooling is then used to concatenate the feature vectors before classification. While
- 9 max pooling is simple and computationally efficient, it cannot deal with pose variance and does not
- 10 model the relationship between slices.
- An alternative method to pooling is treating the scans as 3D, such as in CoviNet<sup>39</sup>. CoviNet takes the 11
- 12 whole scan and uses a 16 layer 3D CNN followed by pooling and fully connected layers. We
- 13 implemented these models as described in their respective papers.
- 14 In all comparison experiments, we kept hyperparameters, such as learning rate, learning rate decay,
- 15 and data augmentation, the same to ensure the comparisons were fair. For COVNet<sup>7</sup> and the model
- 16 proposed by Bai et al.,<sup>8</sup> we pretrained the CNNs on ImageNet as they also did; however, no
- 17 pretrained models were available for CoviNet. For the loss function, we also used the Brier score.<sup>24</sup>
- 18 Computing
- 19 Models were developed using an Amazon Web Services p3.8xlarge node with four Tesla V100 16GiB
- 20 GPUs and 244GiB available memory. Model inference was performed on a local Linux machine
- 21 running Ubuntu 18.04, with a Titan X 12GiB GPU and 32GiB available memory. Model development
- and inference were performed using Tensorflow 2.4,<sup>40,41</sup> and R 4.0.5<sup>29</sup> was used to produce 22
- evaluation metrics<sup>42 43</sup> and graphs.<sup>34 44</sup> We used mixed precision to reduce the computational cost, 23
- which uses 16-bit floating-point precision in all layers, except for the mixed-effects and classification 24
- 25 layers, where 32-bit floating-point precision is used.
- We used the Adam optimiser<sup>45</sup> with an initial learning rate of 1e-4; if the internal validation loss did 26
- 27 not improve for three epochs, we reduced the learning rate to 20%. In addition, we assumed
- 28 convergence and stopped training if the loss did not improve for ten epochs to reduce the time
- 29 spent training and the energy used.
- 30 Data
- 31 There is currently no established method for estimating the sample size estimate in deep learning.
- 32 We propose treating the final fully connected classification layer as the model and treating previous
- layers as feature extraction. We can then use the number of parameters in the final layer to estimate 33
- the required sample size. Using the 'pmsampsize' package<sup>46</sup> in R, we estimate the required minimum 34
- 35 sample size in the development set. We use a conservative expected C-statistic of 0.8, with 21
- 36 parameters and an estimated disease prevalence of 80% based on datasets used in other studies.
- 37 This gives a minimum required sample size of 923 patients in the training set. For model validation,
- 38 around 200 patients with the disease and 200 patients without the disease are estimated to be
- needed to assess calibration.<sup>28</sup> 39
- 40 All data used here is retrospectively collected and contains hospital patients with CT scans
- performed during the COVID-19 pandemic. The diagnosis was determined by examining radiological 41
- features of the CT scan for signs of COVID-19, such as ground-glass opacities. For model 42
- development, we use the MosMed dataset,<sup>47</sup> which consists of a total of 1,110 CT scans displaying 43
- 44 either healthy or COVID-19 infected lungs. The scans were performed in Moscow hospitals between

perpetuity. It is made available under a CC-BY 4.0 International license .

- March 1, 2020, and April 25, 2020. We split the dataset into two sets for training and internal 1
- 2 validation on the patient level. The training set is used to train the model, and the internal validation
- 3 set is used to select the best model based on the loss at each epoch; this helps prevent overfitting on
- 4 the training set. In addition, we obtained images from a publicly available dataset published by
- Zhang et al.<sup>48</sup> consisting of CT images from a consortium of Chinese hospitals. 5
- 6 Overall, this allows us to perform external geographical validation in another country and to better
- 7 evaluate the developed model. In addition, we will be able to assess how well a deep learning model
- 8 generalises to other populations. A summary of all the datasets used is shown in Table 1. We have
- 9 923 patients in the training set and at least 200 patients in each class for the external validation set.
- 10 Table 1: Summary of the datasets used.

Dataset	Location	Use	Healthy/COVID19
MosMed Training	Moscow, Russia	Training	169/856
<b>MosMed Validation</b>	Moscow, Russia	Internal Validation	85/285
Zhang et al. <sup>48</sup>	China	External Validation	243/553

11

12



13 14



(a)

(b)

- Figure 2: Example images showing (a) healthy and (b) COVID-19 lungs taken from the Mosmed 17 18 dataset.
- 19 Data pre-processing and augmentation
- 20 The MosMed dataset was converted from Dicom image format into PNG, normalised to have a mean
- 21 of 120 and a variance of 95. Images were ordered from the top of the lungs to the bottom. During
- 22 training, we applied random online data augmentation to the images. This alters the image slightly
- 23 and gives the effect of increasing the training dataset size, although this is not as good as expanding
- 24 the training dataset with more samples. First, we adjusted the brightness and contrast between 80%
- 25 and 120%. We then rotated the image plus or minus 5 degrees and cropped the image up to 20% on

perpetuity. It is made available under a CC-BY 4.0 International license .

- 1 each side. Finally, we flipped the image horizontally and vertically with a probability of 50% each. All
- 2 random values were chosen using the uniform distribution except for the flips, which were chosen
- 3 using a random bit.
- The dataset taken from Zhang et al.<sup>48</sup> required a large amount of sorting to be made suitable for use. 4
- 5 Some of the scans were pre-segmented and only showed the lung areas, while others showed the
- 6 whole CT scan. We removed any pre-segmented images. Identifying information on some images
- 7 had to be cropped to reduce bias in the algorithm. In addition, many of the scans were duplicates
- 8 but were not labelled as such, and many scans were incomplete, only showing a few lung slices or
- 9 not showing any lung tissue at all. We only used complete scans with one scan per patient. Finally,
- 10 some scans needed to be ordered top to bottom. Using the bilinear sampling algorithm, all images
- 11 were resized to 256 by 256 pixels, and image values were divided by 255 to normalise between 0
- 12 and 1.
- 13 The MosMed dataset has a median of 41 slices, a minimum of 31 slices and a maximum of 72 slices.
- 14 The Zhang et al. dataset has much greater variability in scan size with a median of 61 slices, a
- 15 minimum of 19 slices, and a maximum of 415 slices. We present histograms showing the number of
- 16 slices per scan in Figure 3. We require a fixed number of slices as input, and we chose 20 as the slice
- 17 size. For all scans, we included the first and last images. If scans had more than 20 slices, we sampled
- 18 uniformly to select 20. Only one scan in the Zhang et al. dataset had less than 20 slices; a blank slice
- 19 replaced this slice; the mixed-effects model can account for missing data.



Figure 3: Histogram showing the number of slices per scan for (a) the MosMed<sup>47</sup> dataset and (b) the 22 Zhang et al.<sup>48</sup> dataset. The MosMed dataset has much fewer slices on average with a much smaller 23

24 spread.

20

21

### Results 25

- 26 On the internal validation dataset, the proposed model attained an AUROC of 0.936 (95%CI: 0.910,
- 27 0.961). Using a probability threshold of 0.5, the sensitivity, specificity, NPV, and PPV were 0.753
- 28 (0.647, 0.840), 0.909 (0.869, 0.940), 0.711 (0.606, 0.802), and 0.925 (0.888, 0.953), respectively. The
- 29 model proposed by Bai et al.<sup>8</sup> attained an AUROC of 0.731 (0.674, 0.80). However, despite attaining
- 30 a reasonably AUC value, the model was badly calibrated, and the predicted probabilities of COVID-19
- 31 were all clustered around 0.42, meaning that the sensitivity, specificity, PPV, and NPV are
- 32 meaningless. We tried to retrain the model and rechecked the code implementation; however, we
- 33 could not obtain more meaningful results. Covinet<sup>9</sup> attained an AUROC of 0.810 (0.748, 0.853). Using

- 1 a probability threshold of 0.5, the sensitivity, specificity, NPV, and PPV were 0.824 (0.726, 0.898),
- 2 0.596 (0.537, 0.654), 0.378 (0.308, 0.452), and 0.919 (0.870 0.954), respectively. COVNet<sup>7</sup> attained
- 3 an AUROC of 0.935 (0.912, 0.959). Using a probability threshold of 0.5, the sensitivity, specificity,
- 4 NPV, and PPV were 1.0 (0.958, 1.0), 0.796 (0.745, 0.842), 0.594 (0.509, 0.676), and 1.0 (0.984, 1.0),
- 5 respectively. Full results for a range of probability thresholds are shown in Table 2.
- 6 Calibration curves in Figure 5 show reasonable calibration for the mixed-effects model, although the
- 7 model may still benefit from some recalibration. The other models do not have good calibration and
- 8 likely provide harmful predictions. The decision curve in Figure 6 shows that the proposed model is
- 9 of great clinical benefit compared to the treat all and treat-none approach.
- 10 It is important to remember that the model was selected using this internal testing set to avoid
- 11 overfitting on the training set; therefore, these results are biased, and the external validation results
- 12 are more representative of the true model performance.
- 13 On the external geographical validation dataset, the proposed model attained an AUROC of 0.930
- 14 (0.914, 0.947). With a probability threshold of 0.5, the sensitivity, specificity, NPV, and PPV were
- 0.778 (0.720, 0.828), 0.882 (0.853, 0.908), 0.744 (0.686, 0.797), and 0.90 (0.872, 0.924), respectively. 15
- 16 The model proposed by Bai et al.<sup>8</sup> again attained a reasonable AUROC of 0.805 (0.774, 0.836);
- 17 however, the sensitivity, specificity, NPV, and PPV were meaningless. Covinet<sup>9</sup> attained an AUROC of
- 18 0.651 (0.610, 0.691). Using a probability threshold of 0.5, the sensitivity, specificity, NPV, and PPV
- 19 were0.008 (0.001, 0.029), 0.991 (0.979, 0.997), 0.286 (0.037, 0.710), and 0.695 (0.661, 0.727),
- 20 respectively. COVNet<sup>7</sup> attained an AUROC of 0.808 (0.775, 0.841). With a cut-off point of 0.5, the
- 21 sensitivity, specificity, NPV, and PPV were 0.387 (0.325, 0.451), 0.940 (0.917, 0.959), 0.740 (0.655,
- 22 0.814), and 0.777 (0.744, 0.808), respectively. Full results are shown in Table 3.
- 23 Similar to the internal validation, Figure 7 shows reasonable calibration for the mixed-effects model,
- 24 although some recalibration may improve performance. Again, the comparison models could give
- 25 harmful predictions as they are poorly calibrated. The decision curve in Figure 8 shows that the
- 26 model is of great clinical benefit compared to the treat all and treat-none approach.
- 27 Although our proposed method and the Covnet model showed comparable performance on the
- 28 internal validation set, the Covnet model could not generalise to the external geographical validation
- 29 set, and calibration showed that the Covnet model would provide harmful risk estimates. This
- 30 highlights the need for robust external validation in each intended setting. Nevertheless, the results
- 31 show that the proposed method better generalises to external geographical datasets and provides
- 32 less harmful predictions when compared to the four previously proposed methods based on the
- 33 calibration curves.
- 34

**Table 2:** Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value

2 (NPV) on the internal validation dataset. Point estimates and 95% confidence intervals were calculated using De Long's method for AUROC and Jeffrey's

3 interval for sensitivity, specificity, PPV, and NPV. Results are shown at a range of probability thresholds.

Model	AUROC	Threshold	Sensitivity	Specificity	PPV	NPV
Bai et al	0.731	0.3	0 .0 (0.0, 0.042)	1.0 (0.987, 1.0)	NA	0.77 (0.724, 0.812)
	(0.674, 0.80)	0.4	0.012 (0, 0.064)	0.996 (0.981, 1.0)	0.50 (0.013, 0.987)	0.772 (0.725, 0.814)
		0.5	1.0 (0.958, 1.0)	0.0 (0.0, 0.013)	0.230 (0.188, 0.276)	NA
		0.6	1.0 (0.958, 1.0)	0.0 (0.0, 0.013)	0.230 (0.188, 0.276)	NA
		0.7	1.0 (0.958, 1.0)	0.0 (0.0, 0.013)	0.230 (0.188, 0.276)	NA
CoviNet	0.801	0.3	0.459 (0.350, 0.570)	0.898 (0.857, 0.931)	0.574 (0.448, 0.693)	0.848 (0.802, 0.886)
	(0.748, 0.853)	0.4	0.706 (0.597, 0.80)	0.761 (0.708, 0.810)	0.469 (0.380, 0.559)	0.897 (0.851, 0.932)
		0.5	0.824 (0.726, 0.898)	0.596 (0.537, 0.654)	0.378 (0.308, 0.452)	0.919 (0.870 0.954)
		0.6	0.918 (0.838, 0.966)	0.446 (0.387, 0.505)	0.331 (0.271, 0.394)	0.948 (0.895, 0.979)
		0.7	0.965 (0.90, 0.993)	0.246 (0.197, 0.30)	0.276 (0.226, 0.331)	0.959 (0.885, 0.991)
CovNet	0.935	0.3	0.941 (0.868, 0.981)	0.839 (0.791, 0.879)	0.635 (0.544, 0.719)	0.98 (0.953, 0.993)
	(0.912, 0.959)	0.4	0.965 (0.90, 0.993)	0.825 (0.775, 0.867)	0.621 (0.533, 0.704)	0.987 (0.964, 0.997)
		0.5	1.0 (0.958, 1.0)	0.796 (0.745, 0.842)	0.594 (0.509, 0.676)	1.0 (0.984, 1.0)
		0.6	1.0 (0.958, 1.0)	0.779 (0.726, 0.826)	0.574 (0.490, 0.655)	1.0 (0.984, 1.0)
		0.7	1.0 (0.958, 1.0)	0.761 (0.708, 0.810)	0.556 (0.473, 0.636)	1.0 (0.984, 1.0)
Mixed-Effects	0.936	0.3	0.588 (0.476 0.694)	0.961 (0.932, 0.981)	0.820 (0.70, 0.906)	0.887 (0.846, 0.920)
(Ours)	(0.910, 0.961)	0.4	0.659 (0.548, 0.758)	0.933 (0.898, 0.959)	0.747 (0.633, 0.840)	0.902 (0.862, 0.933)
		0.5	0.753 (0.647, 0.840)	0.909 (0.869, 0.940)	0.711 (0.606, 0.802)	0.925 (0.888, 0.953)
		0.6	0.812 (0.712, 0.888)	0.884 (0.841, 0.919)	0.676 (0.577, 0.766)	0.940 (0.905 0.960)
		0.7	0.906 (0.823 0.958)	0.832 (0.783, 0.873)	0.616 (0.525, 0.702)	0.967 (0.937, 0.986)

**Table 3:** Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value

2 (NPV) on the external validation dataset. Point estimates and 95% confidence intervals were calculated using De Long's method for AUROC and Jeffrey's

3 interval for sensitivity, specificity, PPV, and NPV. Results are shown at a range of probability thresholds.

Model	AUROC	Threshold	Sensitivity	Specificity	PPV	NPV
Bai et al	0.805 (0.774, 0.836)	0.3	0.0 (0.0, 0.015)	1.0 (0.993, 1.0)	NA	0.695 (0.661, 0.727)
		0.4	0.0 (0.0, 0.015)	1.0 (0.993, 1.0)	NA	0.695 (0.661, 0.727)
		0.5	1.0 (0.985, 1.0)	1.0 (0.0, 0.007)	0.305 (0.273, 0.339)	NA
		0.6	1.0 (0.985, 1.0)	1.0 (0.0, 0.007)	0.305 (0.273, 0.339)	NA
		0.7	1.0 (0.985, 1.0)	1.0 (0.0, 0.007)	0.305 (0.273, 0.339)	NA
CoviNet	0.651 (0.610, 0.691)	0.3	0.0 (0.0, 0.015)	1.0 (0.993, 1.0)	NA	0.695 (0.661, 0.727)
		0.4	0.0 (0.0, 0.015)	1.0 (0.993, 1.0)	NA	0.695 (0.661, 0.727)
		0.5	0.008 (0.001, 0.029)	0.991 (0.979, 0.997)	0.286 (0.037, 0.710)	0.695 (0.661, 0.727)
		0.6	0.160 (0.117, 0.213)	0.929 (0.905, 0.949)	0.50 (0.385, 0.615)	0.716 (0.681, 0.749)
		0.7	0.551 (0.487, 0.615)	0.694 (0.654, 0.733)	0.442 (0.385, 0.50)	0.779 (0.740, 0.815)
CovNet	0.808 (0.775, 0.841)	0.3	0.305 (0.247, 0.367)	0.969 (0.951, 0.982)	0.813 (0.718, 0.887)	0.760 (0.727, 0.791)
		0.4	0.354 (0.294, 0.418)	0.955 (0.934, 0.971)	0.775 (0.686, 0.849)	0.771 (0.737, 0.802)
		0.5	0.387 (0.325, 0.451)	0.940 (0.917, 0.959)	0.740 (0.655, 0.814)	0.777 (0.744, 0.808)
		0.6	0.432 (0.369, 0.497)	0.937 (0.913, 0.956)	0.750 (0.670, 0.819)	0.790 (0.756, 0.820)
		0.7	0.473 (0.409, 0.538)	0.931 (0.907, 0.951)	0.752 (0.675, 0.818)	0.801 (0.768, 0.831)
Mixed-Effects (Ours)	0.930 (0.914, 0.947)	0.3	0.675 (0.612, 0.733)	0.935 (0.911, 0.954)	0.820 (0.760, 0.871)	0.867 (0.838, 0.894)
		0.4	0.741 (0.681, 0.795)	0.904 (0.877, 0.927)	0.773 (0.713, 0.825)	0.888 (0.859, 0.913)
		0.5	0.778 (0.720, 0.828)	0.882 (0.853, 0.908)	0.744 (0.686, 0.797)	0.90 (0.872, 0.924)
		0.6	0.827 (0.774, 0.873)	0.859 (0.827, 0.887)	0.720 (0.664, 0.772)	0.919 (0.892, 0.941)
		0.7	0.885 (0.838, 0.922)	0.828 (0.794, 0.859)	0.694 (0.639, 0.744)	0.942 (0.918, 0.961)







Figure 5: Calibration curves for (a) the Bai et al.<sup>8</sup> model (b) the Covinet model<sup>9</sup>, (c) the Covnet model<sup>7</sup>, (d) the proposed mixed-effects model on the Mosmed internal validation dataset.



2 Figure 6: Decision curves for the proposed mixed-effects model on the Mosmed internal validation 3 dataset.









1

- 2 Figure 8: Decision curves for the proposed mixed-effects model on the Zhang et al. external
- 3 validation dataset.
- 4 Saliency maps
- 5 It is vital to understand how the algorithm makes decisions and to check that it identifies the correct
- 6 features within the image. Saliency maps can be used as a visual check to see what features the
- 7 algorithm is learning. For example, the saliency maps in Figure 9 show that the model correctly
- 8 identifies the diseased areas of the scans. We used 100 samples with a smoothing noise of 0.05 to
- 9 create these saliency maps.

10











1 2

3

Figure 9: Example of original images and saliency maps showing highlighted regions on four patients

- 4 (a, b, c, and d) in the Zhang et al.<sup>48</sup> dataset. Four consecutive slices display how the diseased areas
- 5 differ between slices. All images are taken from the external validation set.
- 6 Sensitivity analysis
- 7 Mixed-effects models are capable of accounting for missing data. However, only one image had less
- 8 than 20 slices; hence, we could not adequately assess if our model can indeed maintain good
- 9 performance with missing data. Here, we rerun the analysis using the same dataset, using the same
- 10 model and weights; however, we reduce the number of slices available as testing data inputs to
- 11 simulate missing data. Blank images replace these slices. We uniformly sampled the slices choosing
- 12 between 10 and 19 slices; this equates to between 5 and 50% missing data for the model. We ran
- 13 inference at each level of missingness and briefly show the AUROC to determine at which point the
- 14 predictive performance is significantly reduced.
- 15 The plot of AUROCs at different levels of missingness is shown in Figure 10, along with 95%
- 16 confidence intervals. We can see that at 20% missingness, there is a statistically significant decrease
- 17 in predictive performance. Although, even at 50% missingness, the model still performs relatively
- 18 well, with an AUROC of 0.890 (95% CI: 0.868, 0.912). It should be noted that this does not mean that
- 19 there is no reduction in performance at 5-15% missingness, only that the reduction was not
- 20 statistically significant at the 95% confidence level.
- Deep learning models can be susceptible to adversarial attacks<sup>49</sup>, where minor artefacts or noise on 21
- 22 an image can cause the image to be misclassified, even when the image does not look significantly
- 23 different to a human observer. Here, we perform a brief sensitivity analysis by adding a small
- 24 Gaussian noise to the image. We tested the model performance on the external dataset, with each
- 25 image having a random Gaussian noise added. Experiments were conducted with standard
- 26 deviations of 0 up to 0.005 in increments of 0.001 added to the normalised image. We did not add
- 27 Gaussian noise in the data augmentation so that the model is not explicitly trained to deal with this
- 28 kind of attack.
- When using a variance of 0, the images are unchanged, and the results are the same as the standard 29
- results above. We present results on the Zhang et al.<sup>48</sup> dataset. Example images for each level of 30
- variance are shown in Figure 11, and a graph showing the reduction in AUROC is shown in Figure 12. 31



Figure 10: AUROC values at different levels of missingness. At 20% missingness, the loss in

- performance becomes statistically significant; however, even with 50% missing images, the model
- still has a reasonably high AUROC.







Figure 11: Example images showing the effect of increasing the amount of noise in the image input. 

Noise is increased by increasing the standard deviation (s.d.) of the Gaussian noise. (a) s.d.=0; (b)

s.d.=0.001; (c) s.d.=0.002; (d) s.d.=0.003; (e) s.d.=0.004; (f) s.d.=0.005.





2 **Figure 12:** Graph showing the drop in AUROC as the amount of noise in the image input increases.

0.002

Gaussian Noise Standard Deviation

0.004

3 The AUROC falls steadily with increased noise in the image.

0.000

### 4 Discussion

0.850

0.825

5 Artificial intelligence is set to revolutionise healthcare, allowing large amounts of data to be

6 processed and analysed automatically, reducing pressure on stretched healthcare services. These

7 tools can aid clinicians in monitoring and managing both common conditions and outbreaks of novel

8 diseases. However, these tools must be assessed adequately, and best practice guidelines for

9 reporting and development must be followed closely to increase reproducibility and reduce bias. We

10 have developed a deep learning model to classify CT scans as healthy or COVID-19 using a novel

11 mixed-effects model. Following best practice guidelines, we have externally validated the model. In

12 addition, we robustly externally geographically validated the developed model in several

13 performance areas, which are not routinely reported. For example, discriminative performance

14 measures show that the model can discriminate between healthy and COVID-19 CT scans well,

calibration shows that the model is not clinically harmful. Finally, the clinical usefulness measures

16 show that the model may be useful in a clinical setting. From the results presented here, it would

17 seem that our deep learning model outperforms the RT-PCR tests as shown in the review by Watson

18 et al. <sup>3</sup>; however, those results are conservative estimates and were conducted under real-world

19 clinical settings. A prospective study is required to determine if this is the case.

20 Compared to previously proposed models, our model showed similar discriminative performance to

21 one existing method; however, our method generalised better to an external geographical validation

set and showed improved calibration performance. Interestingly, in both internal and external

validation, the sensitivity and NPV are similar in all models. However, the specificity and PPV are

24 statistically significantly improved for the mixed-effects model in the external validations dataset.

25 The performance of the proposed model in the external validation set is similar to that reported by

26 PCR testing<sup>3</sup>. However, a direct comparison should not be made as PCR testing on this exact dataset

27 is unavailable.

perpetuity. It is made available under a CC-BY 4.0 International license .

- There are several limitations of the study that should be highlighted and improved in future work. 1
- 2 Firstly, we have only performed external geographical validation in a single dataset. Further external
- 3 validation, both geographical and temporal, is needed on many datasets to determine if the model is
- 4 correct in each intended setting. Although we performed a brief sensitivity analysis here, more
- 5 extensive work on adversarial attacks is needed. Future studies could consider following the method
- proposed by Goodfellow et al.<sup>49</sup> to improve robustness against adversarial examples. Patient 6
- 7 demographic data were not available for this study, but future studies could incorporate this data
- 8 into the model to improve results. Finally, rules of thumb for assessing sample size calculations in
- 9 the validation set can lead to imprecise results<sup>50</sup>. Simulating data is a better alternative; however, it
- 10 is difficult to anticipate the distribution of the model's linear predictor. Therefore, we were required to revert to the rule of thumb using a minimum of 200 samples in each group<sup>28</sup>. 11
- Initial experiments used the Zhang et al.<sup>48</sup> dataset for training; this showed promising results on the 12
- internal validation set; however, external validation showed random results. In addition, saliency 13
- 14 maps showed that the model was not using the features of COVID-19 to make the diagnosis and was
- 15 instead using the area around the image. We concluded that the images for each class were slightly
- 16 different, perhaps due to different imaging protocols, and the algorithm was learning the image 17
- format rather than the disease. We then used the MosMed dataset for training and the Zhang et al.<sup>48</sup> dataset for external validation. This highlights the need for good quality training data and 18
- 19 external validation and visualisation.
- 20 Future studies should validate models and follow reporting guidelines such as TRIPOD<sup>17</sup> or the
- upcoming QUADAD-AI<sup>51</sup> and TRIPOD-AI<sup>52</sup> to bring about clinically useful and deployable models. 21
- Further research could look deeper into the areas of images identified by the algorithm as shown on 22
- 23 the saliency maps; this could potentially identify new features of COVID-19 which have gone
- 24 unnoticed. Before any model can be fully deployed, clinical trials are needed to study the full impact
- 25 of using such algorithms to diagnose COVID-19 and the exact situations in which such a model may
- 26 be used. In-clinic prospective studies comparing the performance deep learning models with RT-PCR
- 27 and lateral flow tests should be carried out to determine how deep learning compares; this will show 28 whether deep learning could be used as an automated alternative to RT-PCR testing.
- 29 This study indicates that deep learning could be suitable for screening and monitoring of COVID-19
- 30 in a clinical setting; however, validation in the intended setting is vital, and models should not be
- adopted without this. It has been observed that the quality of reporting of deep learning prediction 31
- 32 models is usually very poor; however, with a bit of extra work and by following best practice
- 33 guidelines, this problem can be overcome. This study highlights the importance of robust analysis
- 34 and reporting of models with external validation.
- 35
- References 36
- 37 1. Coronavirus disease 2019 (COVID-19) - Symptoms, diagnosis and treatment | BMJ Best Practice: 38 BMJ Publishing Group; 2020 [Available from: https://bestpractice.bmj.com/topics/en-39 gb/3000201.
- 40 2. Torjesen I. Covid-19 will become endemic but with decreased potency over time, scientists 41 believe. BMJ 2021;372:n494. doi: 10.1136/bmj.n494
- 42 3. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ 2020;369:m1808. doi: 43 10.1136/bmj.m1808

1 2	4. Mallett S, Allen AJ, Graziadio S, et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant
З	data BMC Medicine 2020:18(1):346 doi: 10.1186/s12916-020-01810-8
4	5 Ruan 7-R Gong P. Han W. et al. A case of coronavirus disease 2019 with twice negative nucleic
т 5	acid testing within 8 days. Chinese Medical Journal 2020:133(12)
6	6 Dentone C. Scafuri S. Mancini ME. et al. Pole of computed temography in COVID 10. / Cardiovass
0	6. Pontone G, Scaruf S, Manchill Mc, et al. Role of computed tomography in COVID-19. J Caralovasc
/	
8	7. Li L, Qin L, Xu Z, et al. Using Artificial Intelligence to Detect COVID-19 and Community-acquired
9	Pheumonia Based on Pulmonary C1: Evaluation of the Diagnostic Accuracy. Radiology
10	2020;296(2):E65-E71. doi: 10.1148/radiol.2020200905
11	8. Bai HX, Wang R, Xiong Z, et al. Artificial Intelligence Augmentation of Radiologist Performance in
12	Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT. Radiology
13	2020;296(3):E156-E65. doi: 10.1148/radiol.2020201491
14	9. Mittal B, Oh J. CoviNet: Covid-19 diagnosis using machine learning analyses for computerized
15	tomography images. Thirteenth International Conference on Digital Image Processing (ICDIP
16	2021) 2021;11878:1187816.
17	10. MacCormick IJC, Zheng Y, Czanner S, et al. Spatial statistical modelling of capillary non-perfusion
18	in the retina. Scientific Reports 2017:7(1):16792. doi: 10.1038/s41598-017-16620-x
19	11. Zhu W. Ku IY. Zheng Y. et al. Spatial linear mixed effects modelling for OCT images: SI ME model
20	Iournal of Imaging 2020;6(6):44
20	12 Albtoush OM Al-Shdefat RB Al-Akaileh A Chest CT scan features from 302 natients with COV/ID-
22	19 in Jordan, Furonean Journal of Radiology Open 2020:7:100295, doi:
22 72	https://doi.org/10.1016/j.oiro.2020.100205
25 24	12 Uscali C. Khalili N. Pakhshavashkaram M. et al. Labar distribution of COVID 10 pnoumania based
24 25	15. Haseli S, Kildilli N, Bakilshayeshkarani N, et al. Lobal distribution of COVID-19 pheumonia based
25	2020.8(1) which are an
20	$2020;\delta(1).000-000$
27	14. Xiang C, Lu J, Zhou J, et al. CT findings in a novel coronavirus disease (COVID-19) pneumonia at
28	initial presentation. BiolNed Research International 2020;2020:5436025. doi:
29	10.1155/2020/5436025
30	15. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of
31	covid-19: systematic review and critical appraisal. <i>BMJ</i> 2020;369:m1328. doi:
32	10.1136/bmj.m1328
33	16. Roberts M, Driggs D, Thorpe M, et al. Common pitfalls and recommendations for using machine
34	learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans.
35	Nature Machine Intelligence 2021;3(3):199-217. doi: 10.1038/s42256-021-00307-0
36	17. Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction
37	model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ : British
38	Medical Journal 2015;350:g7594. doi: 10.1136/bmj.g7594
39	18. Mongan J, Moy L, Kahn CE. Checklist for artificial intelligence in medical imaging (CLAIM): A guide
40	for authors and reviewers. Radiology: Artificial Intelligence 2020;2(2):e200029. doi:
41	10.1148/rvai.2020200029
42	19 Wolff RE Moons KGM Riley RD et al PROBAST: A tool to assess the risk of hias and applicability
7 <u>2</u> //2	of prediction model studies. Annals of Internal Medicine 2019:170(1):51-58. doi:
	10 7226/M12-1276
++ ∕\⊏	10.7320/1910-1370 20. Jiang L. Nguyan T. Linear and generalized linear mixed models and their applications: Coringer
45 16	20. Jiang J, Nguyen T. Linear and generalized inlear mixed models and their applications: Springer
40	2007. 21. Georgely C. Venhauska V. Joffa C. et al. Dathinking the incention and its store for a second starting the initial
47	21. Szegedy C, Vannoucke V, Ione S, et al. Retninking the inception architecture for computer Vision.
48	Proceedings of the IEEE conference on computer vision and pattern recognition 2016:2818-
49	2b.

1	22. Deng J, Dong W, Socher R, et al. ImageNet: A large-scale hierarchical image database. 2009 IEEE
2	Conference on Computer Vision and Pattern Recognition 2009:248-55. doi:
3	10.1109/CVPR.2009.5206848
4	23. Xiong Y, Kim HJ, Singh V. Mixed effects neural networks (MeNets) with applications to gaze
5	estimation. 2019 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR)
6	2019:7735-44. doi: 10.1109/CVPR.2019.00793
7	24. Brier GW. VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY. Monthly
8	Weather Review 1950;78(1):1-3. doi: 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2
9	25. Platt J. Probabilistic outputs for support vector machines and comparisons to regularized
10	likelihood methods. Advances in large margin classifiers 1999;10(3):61-74.
11	26. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: A
12	framework for traditional and novel measures. Epidemiology 2010;21(1)
13	27. Van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive
14	analytics. BMC Medicine 2019;17(1):230. doi: 10.1186/s12916-019-1466-7
15	28. Van Calster B, Nieboer D, Vergouwe Y, et al. A calibration hierarchy for risk models was defined:
16	from utopia to empirical data. Journal of Clinical Epidemiology 2016;74:167-76. doi:
17	https://doi.org/10.1016/j.jclinepi.2015.12.005
18	29. R: A Language and Environment for Statistical Computing [program], 2021.
19	30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas under Two or More Correlated
20	Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics
21	1988;44(3):837-45. doi: 10.2307/2531595
22	31. Stevenson M, Sergeant E, Nunes T, et al. epiR: Tools for the Analysis of Epidemiological Data.
23	2022 doi: <a href="https://CRAN.R-project.org/package=epiR">https://CRAN.R-project.org/package=epiR</a>
24	32. Brown LD, Cai TT, DasGupta A. Interval Estimation for a Binomial Proportion. Statistical Science
25	2001;16(2):101-17.
26	33. Wynants L, van Smeden M, McLernon DJ, et al. Three myths about risk thresholds for prediction
27	models. BMC Medicine 2019;17(1):192. doi: 10.1186/s12916-019-1425-3
28	34. rms: Regression Modeling Strategies [program], 2021.
29	35. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models.
30	Med Decis Making 2006;26(6):565-74. doi: 10.1177/0272989X06295361
31	36. Smilkov D, Thorat N, Kim B, et al. Smoothgrad: Removing noise by adding noise. arXiv 2017. arXiv
32	preprint arXiv:170603825
33	37. He K, Zhang X, Ren S, et al. Deep residual learning for image recognition. <i>Proceedings of the IEEE</i>
34	conference on computer vision and pattern recognition 2016:770-78.
35	38. Efficientnet: Rethinking model scaling for convolutional neural networks. International
36	Conference on Machine Learning; 2019. PMLR.
37	39. Mittal B, Oh J. CoviNet: Covid-19 diagnosis using machine learning analyses for computerized
38	tomography images. <i>ProcSPIE</i> 2021;11878 doi: 10.1117/12.2601065
39	40. Abadi M, Agarwal A, Barham P, et al. Tensorflow: Large-scale machine learning on
40	heterogeneous distributed systems. arXiv preprint arXiv:160304467 2016
41	41. Tensorflow: A system for large-scale machine learning. 12th {USENIX} symposium on operating
42	systems design and implementation ({OSDI} 16); 2016.
43	42. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and
44	compare ROC curves. BMC Bioinformatics 2011;12(1):77. doi: 10.1186/1471-2105-12-77
45	43. Du Z, Hao Y. reportROC: an easy way to report ROC analysis. R package version 3.5, 2020.
46	44. Wickham H. ggplot2: Elegant Graphics for Data Analysis.: Springer-Verlag New York 2016.
47	45. Kingma DP, Ba J. Adam: A method for stochastic optimization. <i>arXiv preprint arXiv:14126980</i>
48	
49 50	46. KIIEV KD, Shell KIE, Ensor J, et al. Minimum sample size for developing a multivariable prediction
5U F1	model: PART II - Dinary and time-to-event outcomes. Statistics in Medicine 2019;38(7):1276-
<b>J</b> T	20. UOI. HLLDS.//UOI.018/10.1002/SIII./332

1 47. Morozov SP, Andreychenko AE, Blokhin IA, et al. MosMedData: Data set of 1110 chest CT scans 2 performed during the COVID-19 epidemic. DD 2020;1(1):49-59. doi: 10.17816/dd46826 3 [published Online First: 2020-12-30] 4 48. Zhang K, Liu X, Shen J, et al. Clinically applicable AI system for accurate diagnosis, quantitative 5 measurements, and prognosis of COVID-19 pneumonia using computed tomography. Cell 6 2020;181(6):1423-33.e11. doi: 10.1016/j.cell.2020.04.045 7 49. Goodfellow IJ, Shlens J, Szegedy C. Explaining and harnessing adversarial examples. arXiv preprint 8 arXiv:14126572 2014 9 50. Snell KIE, Archer L, Ensor J, et al. External validation of clinical prediction models: simulation-10 based sample size calculations were more reliable than rules-of-thumb. Journal of Clinical 11 Epidemiology 2021;135:79-89. doi: 10.1016/j.jclinepi.2021.02.011 12 51. Sounderajah V, Ashrafian H, Rose S, et al. A quality assessment tool for artificial intelligence-13 centered diagnostic test accuracy studies: QUADAS-AI. Nature Medicine 2021;27(10):1663-14 65. doi: 10.1038/s41591-021-01517-0 15 52. Collins GS, Dhiman P, Andaur Navarro CL, et al. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction 16 model studies based on artificial intelligence. BMJ Open 2021;11(7):e048008. doi: 17 18 10.1136/bmjopen-2020-048008